Beam Therapeutics
$24.35
24H
Market Cap
Volume
Supply
Price Chart
About Beam Therapeutics - BEAM
Beam Therapeutics Inc. is a biotechnology company that specializes in the development of precision genetic medicines through the use of its proprietary base editing technology, which enables the rewriting of genetic code to treat diseases at the DNA level. Their research looks to provide therapies by directly targeting and editing single base pairs in the human genome without making double-stranded breaks in the DNA.
What are Beam Therapeutics's core values and mission statement?
Beam Therapeutics Inc.'s core mission is to create a new class of precision genetic medicines based on their proprietary base editing technology, with the aim to provide life-long cures to patients suffering from serious diseases. Their core values revolve around innovation, urgency, and collaboration to effectively harness the power of base editing to make a significant impact on patient health.
Who founded Beam Therapeutics and when?
Beam Therapeutics Inc. was founded by David Liu, Feng Zhang, and J. Keith Joung in 2017.
Who leads Beam Therapeutics?
As of the last update, Beam Therapeutics Inc. was led by CEO Dr. John Evans.
Where is Beam Therapeutics located, and what is its base country?
Beam Therapeutics Inc. is headquartered in Cambridge, Massachusetts, and its base country is the United States.
On which exchanges is Beam Therapeutics traded?
Beam Therapeutics Inc. is traded on the Nasdaq Stock Market under the ticker symbol BEAM.
Historical data
Beam Therapeutics (BEAM) Price Live Data
The live price of Beam Therapeutics (BEAM) is $24.35, with a trading volume of 1,183,199 in the last 24 hours. Wrapstocks updates the BEAM price in real-time. Beam Therapeutics is up 0.16% in the last 24 hours. The company has a live market cap of $1,988,364,928.00 and a supply of 81,657,697 BEAM stocks.
Beam Therapeutics (BEAM) is traded on NASDAQ Stock Exchange, and currently, the market is closed; trading will be resumed in 6 hours and 35 minutes.
